CAMBRIDGE, Mass. – (June 2, 2014) – Scientists at Nuclea Biotechnologies, Inc. and Thermo Fisher Scientific are pooling their expertise to develop novel multiplexed research methods for high-throughput quantification of native insulin and its therapeutic analogs. Monitoring the levels of these markers may be useful in predicting the response to therapy for Type 2 diabetes. Nuclea has extensive experience in developing and commercializing biomarkers and clinical tests. The Thermo Fisher Scientific Biomarker Research Initiatives in Mass Spectrometry (BRIMS) Center has successfully collaborated with numerous leading clinical researchers to apply mass spectrometry (MS) to biomarker discovery and its translation to high-throughput, quantitative methods.
“We’ve already worked with the BRIMS Center to develop two other very important assays,” said Nuclea CEO, Patrick Muraca. “These assays have demonstrated the sensitivity, precision and robustness needed for high-throughput detection of clinically relevant isoforms of target proteins.”
“The real-world application of multiplexed MS-based methods to Type 2 diabetes presents an opportunity to advance research in this crucial area.” said Mary Lopez, director of the BRIMS Center, Thermo Fisher Scientific. “Nuclea’s proven ability to validate and develop routine assays means our collaboration can support research efforts.”
Scientists from Nuclea and the BRIMS Center will develop multiplexed MS-based research methods that Nuclea will use to analyze donor plasma samples from Boston-based diabetes research collaborations. A proprietary platform that combines Thermo Scientific MSIA immuno-enrichment technology, TSQ Vantage or Quantiva triple quadrupole mass spectrometers and Pinpoint Software will be used for the collaborative work.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of $17 billion and 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our four premier brands – Thermo Scientific, Life Technologies, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit www.thermofisher.com.
About Nuclea Biotechnologies, Inc.
Nuclea is headquartered in Pittsfield, Massachusetts with additional operations in Worcester and Cambridge, Massachusetts. Nuclea has developed and is commercializing unique diagnostic tests for colon, breast, leukemia, lung and prostate cancer. Nuclea also performs research leading to novel molecular oncology companion diagnostics for the pharmaceutical and biotechnology industries. http://www.nucleabio.com.
Public Relations Manager
Chromatography and Mass Spectrometry
Thermo Fisher Scientific
355 River Oaks Parkway
San Jose, CA 95134
(408) 965-6408 office
(415) 407-5474 mobile